Genmab A (GMAB) Return on Capital Employed (2020 - 2026)

Genmab A (GMAB) reported Return on Capital Employed of 10.37% for Q1 2026, down 52.74% quarter-over-quarter from 21.94% in Q3 2025.

Genmab A (GMAB) Return on Capital Employed (2020 - 2026) Analysis & Trends

Genmab A has reported Return on Capital Employed for 3 years, with the latest figure at 10.37% in Q1 2026.

For the quarter ending Q1 2026, Return on Capital Employed changed N/A year-over-year to 10.37%; the trailing twelve-month figure through Mar 2026 stood at 10.37% (changed N/A YoY), and the FY2025 full-year result was 12.83%, changed N/A from the prior year.
Return on Capital Employed for Q1 2026 stood at 10.37%, down from 21.94% in the prior quarter.
The five-year high for Return on Capital Employed was 21.94% in Q3 2025, with the low at 10.37% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-	450.31%
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn	51.73%
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-	-107.40%
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn	21.10%
9	Abivax	94.26 Bn	94.26 Bn	-	-50.43%
10	Genmab A	48.34 Bn	46.82 Bn	831.00 Mn	10.37%

Download Data